Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Andrew Senyei

Premium

Complete Genomics' stockholders voted to elect Andrew Senyei to the board of directors for a three-year term until the 2015 annual stockholder meeting. He serves as the managing director at Enterprise Partners Venture Capital. Previously, he was an adjunct associate professor of obstetrics, gynecology, and pediatrics at the University of California, Irvine. He holds an MD from Northwestern University and a BS from Occidental College.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.